What does the drug do?
Triumeq is a drug that is used to treat patients with the human immunodeficiency virus (HIV) and is shown to be safe. It is thought that ancient viruses (retroviruses) have left their genetic material in our DNA during the human evolution. In some people, this old genetic material may become activated and is believed to be a cause of MND.
Phase 3 (LIGHTHOUSE II)
The Phase 3 trial called Lighthouse II is a randomized, double-blind, placebo-controlled study. This means that participants will be randomly allocated to receive a treatment with either Triumeq or a placebo (dummy drug). This is a much larger trial than Lighhouse, expecting to enroll 390 participants, who will take triumeq for a maximum of 24 months. You can find out more about the trial here.
How can I take part in the trial?
The trial is currently recruiting at the following sites:
- London - King's College London
- London - University College London
Please contact the individual trial site, by clicking each site above, for more information on how to take part in the trial.
Previous Clinical Trials
Phase 2 (LIGHTHOUSE)
The Phase 2 trial (called Lighthouse), showed that Triumeq could suppress this genetic reactivation and may slow disease progression in people living with ALS. Triumeq was shown to be safe and well tolerated in people living with ALS. You can read more about this trial here.
Sept 2022 - The trial began recruiting in the UK.
Last updated: 15/01/2024